Abstract
Cyclin dependent kinase inhibitors (CDK 4/6) are the mainstay of treatment in metastatic Hormone receptor positive (HR+) HER-2 negative breast cancer, having impressive Progression free survival (PFS) and overall survival (OS) results. The approved agents are Palbociclib, Ribociclib and Abemaciclib. OS data are not yet mature for Abemaciclib. Cost effectiveness of these drugs has not been studied in the Indian context, where most patients resort to out of pocket expenditure (OOP). This study was undertaken to analyse the cost effectiveness of Palbociclib and Ribociclib by calculating the quality adjusted life years (QALY) and Incremental cost effective ratio (ICER).
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
